RXRX

Business Context and Reporting Period

Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Recursion is a clinical-stage "TechBio" company utilizing the Recursion Operating System (OS) to industrialize drug discovery through AI, automation, and massive proprietary datasets. The company focuses on precision oncology, rare diseases, and strategic partnerships with major pharmaceutical firms. A defining event for the period was the business combination with Exscientia plc (closed November 2024), creating a fully integrated platform spanning biology and chemistry.

Key Financial Metrics

Note: The filing text does not provide specific gross margin percentages, but Cost of Revenue was $45.2 million against Operating Revenue of $58.5 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 32% primarily due to the recognition of a $30 million acceptance fee from the Roche/Genentech collaboration for the completion of a neuroscience Phenomap, which was previously constrained.
• Expense Increases:
  • R&D: Increased 30% driven by platform expansion (chemical technology, machine learning, transcriptomics) and the inclusion of Exscientia's operations.
  • G&A: Increased 61% due to higher salaries, $20.5 million in transaction costs related to the Exscientia acquisition, and the inclusion of Exscientia's results.
• Acquisition: Completed the acquisition of Exscientia plc for approximately $630.1 million (primarily stock), adding significant intangible assets ($182 million platform technology, $129 million IPR&D) and goodwill ($97.7 million).
• Liquidity: Cash position improved to $594.3 million, bolstered by a June 2024 public offering ($216.4 million net proceeds) and ATM offerings ($84.0 million net proceeds).

Guidance, Outlook, and Risks

Outlook and Catalysts

• Clinical Milestones: Management anticipates approximately 10 key clinical milestones over the next 18 months.
  • REC-617 (CDK7 inhibitor): Early Phase 1/2 data showed a durable partial response in ovarian cancer; combination studies expected in H1 2025.
  • REC-994 (CCM): Phase 2 data showed safety and exploratory efficacy (lesion volume reduction); regulatory discussions planned for 2025.
  • REC-1245 (RBM39 degrader): First patient dosed in Q4 2024; Phase 1 update expected H1 2026.
• Partnerships: Potential for over $20 billion in future milestone payments from collaborations (Roche, Sanofi, Bayer, Merck KGaA). Recent milestones included $30M from Roche and $15M from Sanofi in 2024.
• Platform Vision: Moving toward a "Virtual Cell" where AI models drive hypothesis generation, with wet labs used primarily for validation.

Material Risks and Contingencies

• Capital Needs: The company expects to incur continued losses and will require substantial additional funding. Management believes current cash is sufficient for at least 12 months.
• Internal Controls: A material weakness in internal control over financial reporting was identified and remains unremediated as of December 31, 2024. It relates to controls over estimated costs and time to completion for revenue recognition on license agreements. Additionally, material weaknesses from the acquired Exscientia business remain unremediated.
• Regulatory & Clinical Risk: No products are approved for commercial sale. Clinical trials carry high failure rates, and regulatory approval is uncertain.
• Integration Risk: Risks associated with integrating Exscientia's operations, culture, and technology within the expected timeframe.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $594.3 million cash balance against the projected burn rate, given the 41% increase in net loss and the need for future capital raises.
• Revenue Recognition: Scrutinize the revenue recognition policies for collaboration agreements (specifically Roche and Sanofi) given the identified material weakness in internal controls regarding cost estimates and completion timelines.
• Exscientia Integration: Assess the progress of the Exscientia integration, specifically the realization of synergies and the remediation of Exscientia's pre-existing internal control weaknesses.
• Clinical Data Validation: Monitor upcoming data readouts for REC-617 and REC-994 to validate the efficacy claims made in the filing, as these are critical value drivers.
• Dilution Risk: Review the terms of the new $500 million "at-the-market" sales agreement with Citigroup and the potential for future equity issuances to fund operations.